If you’re familiar with Vertex Pharmaceuticals (NASDAQ:VRTX), probably the first thing that comes to mind when you think about the big biotech is cystic fibrosis (CF). That’s understandable, considering Vertex’s tremendous success so far has been due to its CF franchise. However, Vertex is also working to expand its horizons well beyond CF. The company’s […]
